Oncology Services
Browse by
Recent Submissions
-
Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: a real-world multicentre UK retrospective analysis
(British Journal of Haematology, Wiley Online., 2023-02-23)Daratumumab, bortezomib and dexamethasone (DVd) is approved for patients with relapsed multiple myeloma following the CASTOR phase 3 clinical trial. This retrospective multicentre analysis assesses the overall response ... -
Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients.
(British Journal of Haematology, Wiley., 2023-01-31)Multiple myeloma (MM) is primarily a disease of the elderly with 43% of the UK's newly diagnosed (NDMM) patients aged 75 years and over.1 The highest incidence rates in the UK in both males and females occur in those aged ... -
Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.
(Journal of Clinical Oncology, American Social of Clinical Oncology, 2013-11-01)Purpose The oral mammalian target of rapamycin inhibitor everolimus demonstrated promising efficacy in a phase II study of pretreated advanced gastric cancer. This international, double-blind, phase III study compared ... -
Acalabrutinib versus investigator's choice in relapsed/refractory chronic lymphocytic leukemia: final ASCEND trial results.
(HemaSphere, Wolters Kluwer., 2022-11-14)Acalabrutinib is a Bruton tyrosine kinase inhibitor approved for patients with chronic lymphocytic leukemia (CLL). ASCEND is the pivotal phase 3 study of acalabrutinib versus investigator's choice of idelalisib plus rituximab ... -
Head and neck cancer patients' experiences of percutaneous endoscopic gastrostomy feeding: a Q-methodology study.
(European Journal of Cancer Care, Wiley., 2012-07-01)Head and neck cancer patients are at high risk of malnutrition and its complications and therefore often undergo non-oral nasogastric or percutaneous endoscopic gastrostomy (PEG) nutrition support. However, there is little ... -
Acalabrutinib versus investigator's choice in relapsed/refractory chronic lymphocytic leukemia: final ASCEND trial results.
(Hemasphere, Wolters Kluwer, 2022-11-14)Acalabrutinib is a Bruton tyrosine kinase inhibitor approved for patients with chronic lymphocytic leukemia (CLL). ASCEND is the pivotal phase 3 study of acalabrutinib versus investigator's choice of idelalisib plus rituximab ... -
Guidance on the management of diarrhoea during cancer chemotherapy.
(The Lancet Oncology., Elsevier., 2014-09-15)Diarrhoea induced by chemotherapy in cancer patients is common, causes notable morbidity and mortality, and is managed inconsistently. Previous management guidelines were based on poor evidence and neglect physiological ... -
Risk of premature menopause after treatment for Hodgkin’s lymphoma.
(Journal of the National Cancer Institute, Oxford Academic., 2014-08-19)Background Modern treatment of Hodgkin’s lymphoma (HL) has transformed its prognosis but causes late effects, including premature menopause. Cohort studies of premature menopause risks after treatment have been relatively ... -
Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
(Journal of Medical Economics, Taylor & Francis., 2016-03-01)Objective: To conduct a cost-effectiveness assessment of lenalidomide plus dexamethasone (Rd) vs bortezomib plus melphalan and prednisone (VMP) as initial treatment for transplant-ineligible patients with newly-diagnosed ... -
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma
(Journal of Oncology Pharmacy Practice, Sage, 2022-09-06)Introduction: Two phase 3 studies demonstrated superior efficacy of intravenous daratumumab (DARA IV) plus bortezomib/melphalan/prednisone (ALCYONE) or lenalidomide/dexamethasone (Rd; MAIA) versus standard-of-care regimens ... -
Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials.
(Blood Advances, American Society of Hematology, 2022-09-13)Immunoglobulin D (IgD) myeloma is a subtype often considered to have adverse features and inferior survival, but there is a paucity of data from large clinical studies. We compare the clinical characteristics and outcomes ... -
Reconfiguration from emergency to urgent elective neurosurgery for glioblastoma patients improves length of stay, surgical adjunct use, and extent of resective surgery.
(Neuro-Oncology Practice, Oxford University Press., 2022-05-02)Background: Glioblastoma (GB) is the most common intrinsic brain cancer and is notorious for its aggressive nature. Despite widespread research and optimization of clinical management, the improvement in overall survival ... -
Rare EGFR exon 20 S768I mutation predicts resistance to targeted therapy: a report of two cases
(Journal of Thoracic Oncology, Elsevier., 2014-10-01)The importance of submitting data of clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in patients with uncommon EGFR mutations has been encouraged.1 In view of this, we present ... -
Is hormone replacement therapy in post-menopausal women associated with a reduced risk of oesophageal cancer?
(United European Gastroenterology Journal, Wiley Online, 2014-10-01)Purpose The rise in oesophageal adenocarcinoma incidence in women with age is delayed compared with men until the post-menopausal period. A matched cohort study was therefore undertaken of post-menopausal women on hormone ... -
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
(The Lancet, Elsevier., 2014-10-01)Background VEGFR-2 has a role in gastric cancer pathogenesis and progression. We assessed whether ramucirumab, a monoclonal antibody VEGFR-2 antagonist, in combination with paclitaxel would increase overall survival in ... -
Cancer and myositis: who, when, and how to screen.
(Best Practice and Research. Clinical Rheumatology, Elsevier., 2022-08-12)Cancer screening in idiopathic inflammatory myopathies (IIMs) is essential because an increased risk of cancer in IIMs has been well demonstrated. However, a consensus regarding cancer screening approaches is lacking. ... -
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer.
(Annals of Oncology, Elsevier, 2014-11-01)Background Iniparib is a novel anticancer agent initially considered a poly (ADP-ribose) polymerase (PARP) inhibitor, but subsequently shown to act via non-selective protein modification through cysteine adducts. This ... -
Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer (HIVEC-II): a phase 2, open-label, randomised controlled trial.
(European Urology, Elsevier, 2022-08-20)Background: Adjuvant intravesical chemotherapy following tumour resection is recommended for intermediate-risk non-muscle-invasive bladder cancer (NMIBC). Objective: To assess the efficacy and safety of adjuvant ... -
Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: horizon scanning.
(Frontiers in Surgery, Frontiers Media, 2022-07-26)Introduction: Non-muscle-invasive bladder cancer (NMIBC) is a common and heterogeneous disease; many patients develop recurrent or progress to muscle-invasive disease. Intravesical drug therapy is a pillar in the current ... -
Conference report: improving outcomes for gastrointestinal cancer in the UK.
(Frontline Gastroenterology, BMJ Publishing Group, 2018-01-01)Substantial steps are being made towards early diagnosis. A range of tools are available to help GPs appropriately categorise early symptoms during routine consultations. Various promising new tests and devices are being ...
RSS 1.0